Int J Angiol
DOI: 10.1055/a-2516-2082
Original Article

Association of Left and Right Branch Blocks with Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction

Sukhila Reddy
1   Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, Texas
,
1   Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, Texas
,
Alok Dwivedi
2   Division of Biostatistics and Epidemiology, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center, El Paso, Texas
,
1   Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, Texas
,
1   Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, Texas
› Author Affiliations
Funding This study was funded by the 2023 Internal Medicine SEED Grant by Texas Tech University, El Paso.

Abstract

The associations of left bundle branch block (LBBB) and right bundle branch block (RBBB) with cardiovascular (CV) outcomes compared with normal QRS in heart failure patients with preserved ejection fraction (HFpEF) are unclear. We sought to determine CV morbidity, mortality, and total costs associated with LBBB and RBBB in acute HFpEF compared with those without BBB. A cross-sectional study using the 2019 NIS database analyzed adult HFpEF hospitalizations for acute heart failure, categorizing patients by LBBB, RBBB, or normal QRS. Clinical outcomes included atrial fibrillation (AF), ventricular fibrillation (VF), complete heart block (CHB), sick sinus syndrome (SSS), cardiac arrest (CA), hospitalization costs, and in-hospital mortality. Associations between BBB types and outcomes were assessed using logistic and relative risk (RR) models with propensity score weighting, validated by sensitivity analyses. A total of 334,511 hospitalizations with HFpEF including LBBB (6,818, 2%) and RBBB (7,948, 2.4%) were analyzed. Compared with normal QRS duration, LBBB was associated with VF (odds ratio [OR] = 2.47, p < 0.001), SSS (OR = 1.72, p < 0.001), CHB (OR = 2.77, p < 0.001) and greater hospitalization costs (RR = 1.15, p < 0.001) after adjusting for covariates in PS analysis. Similarly, RBBB was associated with AF (OR = 1.30, p < 0.001), VF (OR = 1.59, p = 0.033), SSS (OR = 1.72, p < 0.001), CHB (OR = 2.81, p < 0.001), CA (OR = 1.19, p < 0.001), and higher hospitalization costs (RR = 1.08, p < 0.001). These associations remained unchanged in multiple validation analyses even after additionally adjusting for obesity, hypertension, and diabetes. The length of stay was shorter in HFpEF with RBBB and LBBB subgroups compared with normal QRS. In hospitalizations of acute decompensated HFpEF, BBB was associated with an increased risk of CV outcomes and hospitalization costs.

Authors' Contributions

S.R. and L.K. wrote the manuscript and conducted the literature review. S.R., D.M., and A.D. conceived the idea. A.D. performed statistical analysis, assisted in manuscript development, critically reviewed, and approved the article, and is the article's guarantor. All authors reviewed and approved of the whole manuscript.


Supplementary Material



Publication History

Article published online:
31 January 2025

© 2025. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Eriksson P, Hansson PO, Eriksson H, Dellborg M. Bundle-branch block in a general male population: the study of men born 1913. Circulation 1998; 98 (22) 2494-2500
  • 2 Eriksson P, Wilhelmsen L, Rosengren A. Bundle-branch block in middle-aged men: risk of complications and death over 28 years. The primary prevention study in Göteborg, Sweden. Eur Heart J 2005; 26 (21) 2300-2306
  • 3 Messer AL, Johnson RP, Shreenivas, White PD. Prognosis in bundle branch block. II. A comparison of right and left bundle branch block with a note on the relative incidence of each. Am Heart J 1951; 41 (02) 239-245
  • 4 Schneider JF, Thomas Jr HE, Kreger BE, McNamara PM, Kannel WB. Newly acquired left bundle-branch block: the Framingham study. Ann Intern Med 1979; 90 (03) 303-310
  • 5 Francia P, Balla C, Paneni F, Volpe M. Left bundle-branch block–pathophysiology, prognosis, and clinical management. Clin Cardiol 2007; 30 (03) 110-115
  • 6 Auricchio A, Fantoni C, Regoli F. et al. Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation 2004; 109 (09) 1133-1139
  • 7 Das MK, Cheriparambil K, Bedi A. et al. Prolonged QRS duration (QRS >/=170 ms) and left axis deviation in the presence of left bundle branch block: A marker of poor left ventricular systolic function?. Am Heart J 2001; 142 (05) 756-759
  • 8 Tang AS, Wells GA, Talajic M. et al. Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363 (25) 2385-2395
  • 9 Heidenreich PA, Bozkurt B, Aguilar D. et al. ACC/AHA Joint Committee Members. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022; 145 (18) e895-e1032
  • 10 Dahal R, Nickel N, Mukherjee D, Alkhateeb H. Current updates in the pharmacotherapy of heart failure with a preserved ejection fraction. Cardiovasc Hematol Disord Drug Targets 2022; 22 (02) 87-95
  • 11 Mares A, Rodriguez T, Deoker A, Lehker A, Mukherjee D. Effect of mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction and with reduced ejection fraction: a narrative review. Curr Vasc Pharmacol 2022; 20 (01) 46-51
  • 12 Adabag S, Rector TS, Anand IS. et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2014; 16 (11) 1175-1182
  • 13 Danciu SC, Gonzalez J, Gandhi N, Sadhu S, Herrera CJ, Kehoe R. Comparison of six-month outcomes and hospitalization rates in heart failure patients with and without preserved left ventricular ejection fraction and with and without intraventricular conduction defect. Am J Cardiol 2006; 97 (02) 256-259
  • 14 Dwivedi AK, Vishwakarma D, Dubey P, Reddy S. Association of polycystic ovary syndrome with cardiovascular disease among female hospitalizations in the United States. Eur J Endocrinol 2023; 188 (06) 555-563
  • 15 Dwivedi AK, Shukla R. Evidence-based statistical analysis and methods in biomedical research (SAMBR) checklists according to design features. Cancer Rep (Hoboken) 2020; 3 (04) e1211
  • 16 Xiao HB, Roy C, Fujimoto S, Gibson DG. Natural history of abnormal conduction and its relation to prognosis in patients with dilated cardiomyopathy. Int J Cardiol 1996; 53 (02) 163-170
  • 17 Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol 2005; 46 (12) 2183-2192
  • 18 Moss AJ, Hall WJ, Cannom DS. et al. MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361 (14) 1329-1338
  • 19 Bristow MR, Saxon LA, Boehmer J. et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350 (21) 2140-2150
  • 20 Sze E, Samad Z, Dunning A. et al. Impaired recovery of left ventricular function in patients with cardiomyopathy and left bundle branch block. J Am Coll Cardiol 2018; 71 (03) 306-317
  • 21 Santos AB, Kraigher-Krainer E, Bello N. et al. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J 2014; 35 (01) 42-47
  • 22 Chung ES, Katra RP, Ghio S. et al. Cardiac resynchronization therapy may benefit patients with left ventricular ejection fraction >35%: a PROSPECT trial substudy. Eur J Heart Fail 2010; 12 (06) 581-587
  • 23 Lund LH, Jurga J, Edner M. et al. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J 2013; 34 (07) 529-539
  • 24 Donal E, Lund LH, Oger E. et al. KaRen Investigators. Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study. Arch Cardiovasc Dis 2014; 107 (02) 112-121
  • 25 Joseph J, Claggett BC, Anand IS. et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC Heart Fail 2016; 4 (06) 477-486
  • 26 Penicka M, Kocka V, Herman D, Trakalova H, Herold M. Cardiac resynchronization therapy for the causal treatment of heart failure with preserved ejection fraction: insight from a pressure-volume loop analysis. Eur J Heart Fail 2010; 12 (06) 634-636
  • 27 Mathew D, Agarwal S, Sherif A. Impact of left bundle branch block on heart failure with preserved ejection fraction. Pacing Clin Electrophysiol 2023; 46 (05) 422-424
  • 28 Sipahi I, Chou JC, Hyden M, Rowland DY, Simon DI, Fang JC. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J 2012; 163 (02) 260-7.e3
  • 29 Cunnington C, Kwok CS, Satchithananda DK. et al. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials. Heart 2015; 101 (18) 1456-1462
  • 30 Friedman DJ, Al-Khatib SM, Dalgaard F. et al. Cardiac resynchronization therapy improves outcomes in patients with intraventricular conduction delay but not right bundle branch block: a patient-level meta-analysis of randomized controlled trials. Circulation 2023; 147 (10) 812-823